LBA01-07 OVERALL SAFETY AND INCIDENCES OF ADVERSE EVENTS BY TIME INTERVAL WITH DAROLUTAMIDE PLUS ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE PHASE 3 ARASENS TRIAL

Authors :: E. David Crawford
Matthew R. Smith
Bertrand Tombal
Karim Fizazi
Maha Hussain
Cora N. Sternberg
Arash Rezazadeh Kalebasty
Ronald Tutrone
Neal D. Shore
Laurence Belkoff
Silke Thiele
Rui Li
Iris Kuss
Heikki Joensuu
Fred Saad
Source :: Journal of Urology. 207
Publication Year :: 2022
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2022.

Tools